Analyst Reco. Cytek Biosciences, Inc.

Equities

CTKB

US23285D1090

Market Closed - Nasdaq Other stock markets 16:30:00 2024-05-03 EDT			5-day change	1st Jan Change
6.22 ^USD	+0.32%		+7.99%	-31.80%

03-20	Cytek Biosciences Insider Sold Shares Worth $269,600, According to a Recent SEC Filing	MT
03-19	Cytek Biosciences Appoints William McCombe as CFO, Reaffirms 2024 Guidance	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Cytek Biosciences Insider Sold Shares Worth $269,600, According to a Recent SEC Filing	03-20	MT
Piper Sandler Trims Price Target on Cytek Biosciences to $10 From $11, Maintains Overweight Rating	03-06	MT
Stephens Initiates Cytek Biosciences With Overweight Rating, Price Target is $9	12-14	MT
Morgan Stanley Trims Price Target on Cytek Biosciences to $7 From $8, Maintains Equalweight Rating	11-09	MT
Morgan Stanley Cuts Cytek Biosciences' Price Target to $8 From $13, Keeps Equalweight Rating	23-10-24	MT
Raymond James Initiates Cytek Biosciences With Market Perform Rating	23-07-19	MT
Morgan Stanley Adjusts Price Target on Cytek Biosciences to $13 From $14, Maintains Equal-Weight Rating	23-05-11	MT
Goldman Sachs Adjusts Cytek Biosciences' Price Target to $12 From $14, Keeps Buy Rating	23-05-10	MT
Piper Sandler Adjusts Price Target on Cytek Biosciences to $15 From $18, Maintains Overweight Rating	23-03-07	MT
Morgan Stanley Trims Cytek Biosciences' Price Target to $14 From $15, Maintains Equalweight Rating	23-03-02	MT
Goldman Sachs Adjusts Cytek Biosciences' Price Target to $14 From $16, Keeps Buy Rating	23-03-02	MT
Piper Sandler Adjusts Cytek Biosciences' Price Target to $16 from $12, Maintains Overweight Rating	22-08-18	MT
Morgan Stanley Adjusts Price Target on Cytek Biosciences to $15 From $11, Maintains Equalweight Rating	22-08-12	MT
Goldman Sachs Adjusts Cytek Biosciences' Price Target to $17 From $15, Keeps Buy Rating	22-08-11	MT
Goldman Sachs Raises Cytek Biosciences' Price Target to $15 From $12, Buy Rating Maintained	22-07-14	MT
Piper Sandler Adjusts Price Target on Cytek Biosciences to $12 From $17, Reiterates Overweight Rating	22-05-16	MT
Morgan Stanley Lowers Price Target for Cytek Biosciences to $11 From $18, Maintains Equalweight Rating	22-05-12	MT
Goldman Sachs Lowers Cytek Biosciences Price Target to $12 From $14, Buy Rating Maintained	22-05-12	MT
Goldman Sachs Adjusts Cytek Biosciences' Price Target to $14 from $28, Keeps Buy Rating	22-04-13	MT
Piper Sandler Adjusts Cytek Biosciences' Price Target to $17 From $20, Reiterates Overweight Rating	22-03-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Analyst Reco. Cytek Biosciences, Inc.

Equities

CTKB

US23285D1090

Analyst Reco.

Filters